Karachi, Otsuka Pakistan Limited informed Pakistan Stock Exchange that the Board of Directors of the company held their meeting on September 06, 2022, to consider and decide to transfer a sum of Rs. 150 million to the general reserve of the company from the profits for the year ended June 30, 2022.
Otsuka Pakistan Limited was incorporated in Pakistan as a public limited company and commenced commercial production of Intravenous Solutions in September 1989 at its factory in Hub, Baluchistan.
The Company is engaged in the manufacturing, marketing and distribution of intravenous infusions and trading in pharmaceutical products, nutritional foods and medical equipment. The Company is an indirect subsidiary of Otsuka Pharmaceutical Company Limited, Japan. Therapeutic Drugs are Otsuka Pakistan’s second line of business; currently consist of Pletaal and Mucosta which are being imported in finished form from Korea.
The total numbers of shares are 12,100,000. The Earnings per share is 7.53 in 2020 which was (14.49) in 2019. The Profit after Taxation is 91,066,000 in 2020 which was 175,348,000 in 2019.